Eli Lilly and Company (NYSE:LLY) Shares Sold by Sentry Investment Management LLC

Sentry Investment Management LLC decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 13.4% during the 3rd quarter, Holdings Channel.com reports. The fund owned 3,321 shares of the company’s stock after selling 513 shares during the period. Eli Lilly and Company makes up approximately 1.2% of Sentry Investment Management LLC’s portfolio, making the stock its 11th biggest position. Sentry Investment Management LLC’s holdings in Eli Lilly and Company were worth $2,942,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. increased its holdings in shares of Eli Lilly and Company by 19.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock worth $7,699,000 after acquiring an additional 1,620 shares during the period. Quent Capital LLC boosted its position in shares of Eli Lilly and Company by 5.3% during the first quarter. Quent Capital LLC now owns 4,943 shares of the company’s stock worth $3,846,000 after buying an additional 249 shares during the period. Mutual Advisors LLC increased its position in Eli Lilly and Company by 404.8% in the 1st quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock valued at $48,699,000 after acquiring an additional 50,197 shares during the period. Whittier Trust Co. raised its stake in shares of Eli Lilly and Company by 52.2% during the first quarter. Whittier Trust Co. now owns 75,487 shares of the company’s stock valued at $58,725,000 after purchasing an additional 25,877 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. increased its stake in Eli Lilly and Company by 155.1% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 19,745 shares of the company’s stock valued at $15,361,000 after buying an additional 12,004 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $806.14 on Tuesday. The company’s fifty day moving average is $908.15 and its two-hundred day moving average is $867.39. The company has a market cap of $765.28 billion, a P/E ratio of 87.15, a price-to-earnings-growth ratio of 3.09 and a beta of 0.43. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm’s revenue was up 20.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.10 earnings per share. Equities analysts expect that Eli Lilly and Company will post 13.23 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.65%. Eli Lilly and Company’s dividend payout ratio is 56.22%.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Berenberg Bank increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Citigroup increased their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research note on Friday, October 25th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Bank of America decreased their target price on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a research note on Thursday, October 31st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday, September 16th. Three investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,008.41.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.